TickerFacts.

Inhibrx Biosciences, Inc. (INBX): Revenue

Annual figures by period end, from SEC filings.

$1.30M
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
$1.80M2023-12-31: $1.80M2024-12-31: $200.0K2025-12-31: $1.30M$1.30M
2023-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$1.30M+550.0%2026-03-19, From 2025-01-01
2024-12-31$200.0K-88.9%2026-03-19, From 2024-01-01
2023-12-31$1.80Mn/a2025-03-17, From 2023-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Inhibrx Biosciences, Inc. (INBX)2025-12-31$1.30M+550.0%
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$1.31M+99.2%
Outlook Therapeutics, Inc. (OTLK)2025-09-30$1.41Mn/a
Pluri Inc. (PLUR)2026-06-30$1.02M-24.0%
Prokidney Corp. (PROK)2025-12-31$893.0Kn/m
Humacyte, Inc. (HUMA)2025-12-31$2.04Mn/a
ImageneBio, Inc. (IMA)2025-12-31$800.0K-77.1%
Aligos Therapeutics, Inc. (ALGS)2025-12-31$2.19M-39.5%
Cardiff Oncology, Inc. (CRDF)2025-12-31$593.0K-13.2%

Compare INBX, SCNI, OTLK, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗